Evolus Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EOLS Nasdaq 8731 https://www.evolus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evolus Inc

Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript - Mar 11th, 2023 11:38 am
Q4 2022 Evolus Inc Earnings Call - Mar 9th, 2023 3:12 pm
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates - Mar 8th, 2023 10:35 pm
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Mar 8th, 2023 9:05 pm
Evolus to Participate in the Barclays Global Healthcare Conference - Feb 28th, 2023 1:45 pm
Evolus Initiates Nuceiva® Launch in Germany and Austria - Feb 27th, 2023 1:45 pm
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update - Feb 22nd, 2023 1:45 pm
Evolus Not Affected by Recent Korean Court Ruling - Feb 10th, 2023 4:07 pm
Evolus to Participate in the SVB Securities Global Biopharma Conference - Jan 31st, 2023 1:45 pm
Institutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS) - Jan 30th, 2023 5:02 pm
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines - Jan 30th, 2023 12:09 pm
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance - Jan 28th, 2023 1:00 pm
Evolus Receives Regulatory Approval for Nuceiva® in Australia - Jan 23rd, 2023 2:00 pm
Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress - Jan 23rd, 2023 1:00 pm
Why Evolus Shares Jumped This Week - Jan 20th, 2023 6:54 pm
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook - Jan 19th, 2023 6:15 pm
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration - Jan 18th, 2023 1:45 pm
Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit - Jan 3rd, 2023 3:03 pm
Evolus Extends Term of Credit Facility with Pharmakon Advisors - Dec 8th, 2022 1:45 pm
Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc. - Dec 7th, 2022 3:00 pm